Serina Therapeutics, Inc. (SER)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 130 | - | 14 | 51 |
| Research and development | 3,152 | 2,951 | 2,415 | 1,594 |
| General and administrative | 2,543 | 2,907 | 2,911 | 2,323 |
| Total operating expenses | 5,695 | 5,858 | 5,326 | 3,917 |
| Loss from operations | -5,565 | -5,858 | -5,312 | -3,866 |
| Other non operating expense | - | - | - | 9 |
| Other income, net | - | 47 | - | - |
| Other income, net | 68 | - | 42 | - |
| Interest expense | 9 | - | 16 | 242 |
| Change in fair value of warrants | 956 | -989 | -6,669 | -9,294 |
| Change in fair value of convertible promissory notes | - | - | - | - |
| Total other (expense) income, net | -897 | 1,036 | 6,695 | 9,043 |
| Net (loss) income | -6,462 | -4,822 | 1,383 | 5,177 |
| Net loss attributable to noncontrolling interest | -14 | -9 | -27 | -27 |
| Net (loss) income attributable to serina therapeutics, inc | -6,448 | -4,813 | 1,410 | 5,204 |
| Basic (in shares) | 10,004,000 | 9,756,000 | 8,851,000 | 8,514 |
| Basic (in usd per share) | -0.66 | -0.49 | 0.16 | 0.61 |
| Diluted ( in shares) | 10,004,000 | 9,756,000 | 10,751,000 | 10,157 |
| Diluted (in usd per share) | -0.66 | -0.49 | 0.13 | 0.51 |